Abstract 2040
Background
Cryptogenic Organising Pneumonia (COP) is an understudied lung disease characterised by presence of granulation tissue within the alveolar ducts and alveoli. While prognosis of patients with COP is generally positive there remains a paucity of information on the condition in the academic literature. This abstract presents the largest real-world study of COP in Chronic lymphocytic Leukaemia (CLL) patients to date.
Methods
A retrospective cohort study utilising the IMS Pharmetrics Plus database. A CLL patient cohort was identified using ICD9/10 codes; patients with previous history of COP prior to CLL diagnosis were excluded from the analysis. As a comparator, a random 5% sample of all patients with no history of CLL was taken. Crude Incidence rates (CR) of COP were estimated in both groups. A Poisson regression model (PRM) was fitted to estimate the age and sex adjusted incidence rate ratio (IRR) of experiencing COP in CLL patients versus those with no history of CLL. Tests for trend were conducted for age and sex.
Results
A total of 64,773 CLL and 3,201,48 non-CLL patients were included in the study. The CLL cohort comprised of 59% males with a total of 436 patients experiencing COP. The non-CLL cohort comprised of 47% males with 1,971 patients experiencing COP. The CR of COP in the CLL cohort was 2.4 (95% CI 2.2- 2.61) per 1,000 person years (py) and 0.20 (95% CI 0.19- 0.21) per 1,000 py in the non CLL cohort. An age and sex adjusted PRM estimated an IRR of 7.7 (95% CI 6.9- 8.68, p-value <0.001). A significant trend of increasing COP incidence was observed for age (p-value <0.001). However, no differences found for gender.
Conclusions
This study indicated that CLL patients had a higher rate of experiencing an episode of COP as opposed to non-CLL patients, adjusted for age and sex. As COP is difficult to distinguish from the infectious and non-infectious inflammatory pulmonary process in CLL patients, awareness of this increased risk may lead to earlier diagnosis and institution of treatment of COP. The role of co-morbidities and co-medications will be investigated in further analyses.
Clinical trial identification
Legal entity responsible for the study
Gilead Sciences Gilead Sciences.
Funding
Gilead Sciences.
Editorial Acknowledgement
Disclosure
I. Faghmous, H. Ramroth, C. Aguilar, A. Van Troostenburg, P. Badyal: Gilead Sciences.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract